CRANBURY, N.J. & STONY BROOK, N.Y.--(BUSINESS WIRE)--Cornerstone Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has begun dosing patients in a recently approved safety and early efficacy clinical trial of CPI-613, its novel first-in-class Altered Energy Metabolism-Directed (AEMD) compound being evaluated for potential use in a wide array of cancers. Health Canada and the US FDA have approved the initiation of studies of CPI-613, which will be conducted at clinical trial sites in both the US and Canada.
